A novel micelle-forming material used for preparing a theranostic vehicle exhibiting enhanced in vivo therapeutic efficacy.
A new micelle-forming material, folic acid-conjugated carboxymethyl lauryl chitosan (FA-CLC), and superparamagnetic iron oxide (SPIO) nanoparticles were used for preparing an imaging-guided drug vehicle (the FA-CLC/SPIO hybrid micelle) that demonstrates targeted delivery, imaging, and controlled release of hydrophobic agents. We found that the ratio of viable normal cells to tumor cells was increased prominently after delivery of camptothecin (CPT)-loaded FA-CLC/SPIO micelles and therapeutic sonication. In addition, a magnetic field could enhance the tumor-targeting effect of FA-CLC/SPIO micelles. Therefore, after sequential administration of magnetic attraction to CPT-loaded FA-CLC/SPIO micelles, and therapeutic sonication, the in vivo therapeutic efficacy of CPT was markedly enhanced. However, a nonfocused magnetic field could enhance the undesirable accumulation of iron-containing vehicles in the liver if the tumor (i.e., magnetic attraction site) is near the liver. We propose that magnetic attraction must be carefully applied, far from the liver.
†Institute of Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Hsiao-Ping
HP
Chen
†Institute of Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan, R.O.C.|‡Division of Neurosurgery, Department of Surgery, Taipei Tzu Chi Hospital, Taipei, Taiwan, R.O.C.|§Department of Surgery, School of Medicine, Tzu Chi University, Hualien City, Taiwan, R.O.C.|∥Department of Biomedical Engineering, Ming Chuang University, Taipei, Taiwan, R.O.C.
Ming-Hong
MH
Chen
⊥Department of Orthopaedic Surgery, Taipei City Hospital, Taipei, Taiwan, R.O.C.
Fu-I
FI
Tung
†Institute of Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Tse-Ying
TY
Liu
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D002166:Camptothecin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D002232:Carbocyanines; D045744:Cell Line, Tumor; D048271:Chitosan / Q000031:analogs & derivatives* / Q000737:chemistry*; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005260:Female; D005290:Ferric Compounds / Q000737:chemistry*; D005453:Fluorescence; D005456:Fluorescent Dyes; D005492:Folic Acid / Q000031:analogs & derivatives* / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D057927:Hydrophobic and Hydrophilic Interactions; D060526:Magnetic Fields; D059346:Magnets; D008819:Mice, Nude; D008823:Micelles; D053758:Nanoparticles; D013010:Sonication
D000970:Antineoplastic Agents; C098793:CY5.5 cyanine dye; D002232:Carbocyanines; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005290:Ferric Compounds; D005456:Fluorescent Dyes; D008823:Micelles; C000499:ferric oxide; D048271:Chitosan; D005492:Folic Acid; D002166:Camptothecin